Creyon Bio

The oligonucleotide field builds on milestones from fomivirsen (1998) to patisiran (2018), with chemical modifications now extending half-life and enabling infrequent dosing, yet most candidate sequences still fail on toxicity or immunostimulation. Delivery to the right tissue, including across the blood-brain barrier and into immune cells, remains the binding constraint that Creyon aptamer approach targets.

Large-pharma demand for programmable, safe-by-design siRNA/ASO engines is evidenced by Lilly up-to-1B Creyon collaboration for multi-target discovery. Creyon near-term outlook turns on taking its first candidate into the clinic from its neuromuscular, CNS, and immunology pipeline while competing against other AI-drug-discovery platforms and alternative delivery modalities.

Creyon Bio, Inc. of San Diego (with Research Triangle Park operations) is an operating, venture-backed company whose 40M-plus seed and Series A financing was led by DCVC Bio and Lux Capital with Casdin Capital, Alexandria Venture Investments, and BioBrit participating. Governance links to its lead investors persist via board seats for DCVC Bio and Lux Capital alongside independent director Dennis Langer (director since 2021).

No acquisition, merger, buyout, or acquired-by event naming Creyon as the target appears in 2022-2026 receipted searches or funding-database corroboration. The only control-adjacent item is Lilly minority equity purchase inside the 13M collaboration upfront, which the parties frame as licensing plus research collaboration with per-target candidate rights, while Creyon retains its wholly-owned pipeline under new CEO Serge Messerlian.

Creyon platform combines proprietary, purpose-built pharmacology datasets from in vitro, in vivo, and ex vivo experiments with machine-learning models (branded NuclelQ) that extract design rules for oligonucleotide-based medicines across antisense, siRNA, and DNA/RNA-editing modalities. Its aptamer delivery technology targets payloads to T and B cells and shuttles nucleic acids across the blood-brain barrier, also directing lipid nanoparticles to immune cell types.

The company reports three active wholly-owned pipeline products spanning immunology, central nervous system, and neuromuscular disease, including a transferrin-receptor aptamer CNS program for siRNA/ASO delivery and a first-in-class splice-switching oligonucleotide for late-onset Pompe disease aimed at restoring endogenous GAA production. Programs are preclinical with a first clinical entry guided for the near term.